Please login to the form below

Not currently logged in
Email:
Password:

prostate cancer uk

This page shows the latest prostate cancer uk news and features for those working in and with pharma, biotech and healthcare.

UK start-up Azeria emerges with £4m drug discovery pot for cancer

UK start-up Azeria emerges with £4m drug discovery pot for cancer

The company is focusing on hormone resistant breast and prostate cancer. ... The new drug discovery company is focusing on hormone resistant breast and prostate cancer, and specifically drugs that target ‘pioneer’ transcription factors – which

Latest news

  • Daily Brief:  NICE says no to Zytiga, Genentech and UK biotech sign microbiome deal Daily Brief:  NICE says no to Zytiga, Genentech and UK biotech sign microbiome deal

    UK Market Access. NICE says no to Zytiga. NICE has rejected Janssen’s Zytiga plus androgen deprivation therapy (ADT) for men with untreated high-risk hormone-sensitive metastatic prostate cancer (mHSPC). ... The pharma company and charity Prostate

  • Teva launches online cancer portal My Day Teva launches online cancer portal My Day

    The social media listening research found male prostate cancer patients tended to focus on 'technical details', while female breast cancer patients made greater use of 'emotional' language. ... For breast cancer, its analysts identified 7, 826 posts from

  • The Prostate Project kicks of 2016 OctoBeardFest campaign The Prostate Project kicks of 2016 OctoBeardFest campaign

    Aims to raise awareness and funds for prostate cancer research. The Prostate Project has once again launched its successful OctoBeardFest campaign with the support of long-serving patron the broadcaster Michael ... Currently, the university researchers

  • NICE finally set to back wider use of Ferring's Firmagon NICE finally set to back wider use of Ferring's Firmagon

    Ferring UK's general manager Steve Howson said: “NICE's decision represents a significant step forward, and is very good news for men living with advanced hormone-dependent prostate cancer, who ... Heather Blake, director of support and influencing at

  • NICE changes tack on Sanofi's prostate cancer drug Jevtana NICE changes tack on Sanofi's prostate cancer drug Jevtana

    Medical charity Prostate Cancer UK's Heather Blake said: "It's good news that cabazitaxel is now going to be routinely available to those men who need it. ... The Scottish Medicines Consortium (SMC) is due to deliver a verdict on Jevtana in the coming

More from news
Approximately 0 fully matching, plus 23 partially matching documents found.

Latest Intelligence

  • Deal Watch April 2016 Deal Watch April 2016

    The explanation for this is that Janssen are getting rights only for prostate cancer, not ovarian and breast cancer where the product is in phase III and the rights do not ... 500. Tesaro (US). Janssen (US). License and collaboration. Niraparib PARP

  • Communiqué Awards digital publication Communiqué Awards digital publication

    See which healthcare communications programmes made a real difference to health outcomes with the Communiqué Awards digital publication.

  • Interview: Cesar Rodriguez, Janssen Interview: Cesar Rodriguez, Janssen

    The UK is one of the first markets to launch our new medicines. ... Janssen is developing its strengths in other areas too, and Rodriguez noted the company's recent developments in oncology, including the launch of abiraterone acetate for prostate cancer

More from intelligence
Approximately 0 fully matching, plus 3 partially matching documents found.

Latest from PMHub

  • Caring for prostate cancer patients

    Cancer Research UK estimates that  men in the UK have a 1 in 8 chance of developing prostate cancer  at some point in their lives. It’s the most commonly diagnosed ... From a personal perspective, I’ve watched my grandfather receive his

  • Why is the UK lagging behind the rest of Europe in cancer survival?

    Say Communications, London healthcare PR agency, discusses the latest technologies that will improve cancer survival rates in UK. ... Cancer survival rates are thankfully rising but the UK has been  reported  as falling behind the rest of Europe.

  • Cogora

    Arthritis Research UK. Astrazeneca. Becton Dickinson. Boehringer Ingelheim. Cancer Research UK. ... Nutricia. Orion Pharma. Orphan Europe. Pfizer. Portola. Prostate Cancer UK. Primary Care Respiratory Society.

  • Hayward Medical Communications continues partnership with Prostate Cancer UK

    Improving patient outcomes starts before diagnosis. For this reason, Prostate Cancer UK needed to establish a foothold early in the patient pathway. ... Most recently, Hayward and Prostate Cancer UK have begun a new project to further improve the patient

  • Hayward Medical Communications

    Hayward Medical Communications continues partnership with Prostate Cancer UK. ... I would not hesitate to recommend them.’. Community Awareness Researcher, Prostate Cancer UK.

More from PMHub
Approximately 1 fully matching, plus 4 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
bmore group

OUR PROMISE: BETTER HEALTH FROM TRIAL TO TREATMENT.We are a full service, independent network of specialist agencies under one roof....

Latest intelligence

The relevance of patient perspectives to value
Exploring the evolution of patient involvement in health technology assessment, and the role of the patient voice in market access....
How is the NHS Long-term Plan being put into action?
Steve How, Paul Midgley and Oli Hudson, of Wilmington Healthcare, explore some of the changes that have occurred since the plan was published...
real world studies
The evolution of real-world studies
How industry and regulators are using real-world data...

Infographics